Boosting Vaccine Response in Dialysis Patients Over 60
Treatments studied
Part of Infections, Lungs & breathing clinical trials.
This study tests whether a medication called rapamycin (sirolimus) can help improve your body's response to flu and RSV vaccines. You have end-stage kidney disease and receive dialysis three times a week, and the researchers want to see if this approach keeps you safer from these infections.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 60 years old or older
- You must have end-stage kidney disease and receive in-center dialysis exactly three times per week
- You cannot have had flu, influenza B, or RSV infection in the past 6 months
- You cannot be taking strong immune-suppressing medications (steroids, mycophenolate, azathioprine, or certain other drugs)
- You cannot have a history of serious side effects from sirolimus or certain lung, skin, or heart conditions
- You cannot be allergic to sirolimus (rapamycin) or the flu/RSV vaccines
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well the flu vaccine works in people with kidney failure who are on dialysis compared to healthy people. It will help doctors understand how kidney problems affect the body’s immune response to vaccination.
This trial tests two FDA-approved drugs, rapamycin and everolimus, to see if they can improve immune function in healthy older adults. You may join if you are generally healthy, live independently, and are between 65 and 90 years old.
This trial is testing a stronger combination of four immune-suppressing medicines (including mTOR inhibitors) to help prevent rejection in kidney transplant patients who have a high level of antibodies. It aims to see if this approach works better than standard care for these 'sensitized' patients.
This Phase 2 trial studies whether sirolimus can slow or prevent functional decline (more difficulty with daily activities) in older adults. You may be considered if you’re in the right age range and have no major heart, lung, liver, kidney, or recent bleeding/clotting problems.
This trial tests whether the drug sirolimus (rapamycin) can help people with dilated cardiomyopathy who also have a specific virus (KSHV) in their blood. It aims to see if sirolimus can improve heart function.
This Phase 2 study tests a site-specific immune “booster” in people age 65 and older to help improve natural immunity and reduce respiratory (lung/airway) infections. You may be eligible if you can consent, are in an eligible living situation, and are not currently using certain immune-suppressing medicines.
Hear when a new Haemodialysis Patients trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.